Difference between revisions of "Corona Vaccins First Dose Efficacy"

From Tech
Jump to navigationJump to search
Line 6: Line 6:
 
[https://www.nejm.org/doi/pdf/10.1056/NEJMoa2101765?articleTools=true#page=7 Vaccinated vs Unvaccinated in BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting]
  
[https://www.nejm.org/doi/pdf/10.1056/NEJMoa2101765?articleTools=true#page=7 Vaccinated vs Unvaccinated in BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting]
   
−
[[File:Screenshot 2021-07-11 at 12-37-30 BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting - NEJMoa2101765.png|x200px|Vaccinated vs Unvaccinated in BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting]]
 +
[[File:Screenshot 2021-07-11 at 12-37-30 BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting - NEJMoa2101765.png|x200px]]
   
 
=Moderna=
  
=Moderna=
−
[https://www.fda.gov/media/144434/download#page=28 Vaccines and Related Biological Products Advisory Committee MeetingDecember 17, 2020]
 +
[https://www.fda.gov/media/144434/download#page=28 Vaccines and Related Biological Products Advisory Committee MeetingDecember 17, 2020]
   
−
[[File:Screenshot 2021-07-11 at 11-43-02 Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Bri-...-.png|x200px|Cumulative Incidence Curves for the First COVID-19 Occurrence After Randomization, mITT Set]]
 +
[[File:Screenshot 2021-07-11 at 11-43-02 Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Bri-...-.png|x200px]]
   
 
=AstraZeneca=
  
=AstraZeneca=
Line 20: Line 20:
   
 
[https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know (Oxford/AstraZeneca COVID-19 vaccine AZD1222)]
  
[https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know (Oxford/AstraZeneca COVID-19 vaccine AZD1222)]
  +
  +
=Janssen=
  +
[https://www.nejm.org/doi/full/10.1056/NEJMoa2101544 Cumulative Incidence of Covid-19 with Onset at Least 1 Day after Vaccination and Vaccine Efficacy over Time.]
  +
  +
[[File:Screenshot 2021-07-11 at 14-04-04 Safety and Efficacy of Single-Dose Ad26 COV2 S Vaccine against Covid-19 NEJM.png|x200px]]

Revision as of 13:08, 11 July 2021

Pfizer

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (BNT162b2=Pfizer/BioNTech)

Efficacy of BNT162b2 (Pfizer) against Covid-19 after the First Dose.

Vaccinated vs Unvaccinated in BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Screenshot 2021-07-11 at 12-37-30 BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting - NEJMoa2101765.png

Moderna

Vaccines and Related Biological Products Advisory Committee MeetingDecember 17, 2020

Screenshot 2021-07-11 at 11-43-02 Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Bri-...-.png

AstraZeneca

Cumulative incidence plot for time to first SARS-CoV-2 virologically-confirmed COVID-19 occurring post dose1


Screenshot 2021-07-11 at 13-07-32 Public Assessment Report - UKPAR COVID 19 Vaccine AstraZeneca 23 02 2021 pdf.png

(Oxford/AstraZeneca COVID-19 vaccine AZD1222)

Janssen

Cumulative Incidence of Covid-19 with Onset at Least 1 Day after Vaccination and Vaccine Efficacy over Time.

Screenshot 2021-07-11 at 14-04-04 Safety and Efficacy of Single-Dose Ad26 COV2 S Vaccine against Covid-19 NEJM.png

Retrieved from "http://tech.komputilo.org/index.php?title=Corona_Vaccins_First_Dose_Efficacy&oldid=716"